Company profile
Atara Biotherapeutics, Inc.
NASDAQ: ATRA · Healthcare · Biotechnology
#328 of 1,418 Healthcare companies by revenue34th-percentile growth
EA Score
44DFH 53DQ 33GM 38SS 49
v0.1 · 65/100 weight · provisional
↑ return on assets, operating margin · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$6.2M
Rev growth YoY (TTM)
-96.7%
Net income (FY)
$32.7M
Employees
13
as of 2026-08-18
Market cap
$77.0M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$120.8M$120.8M2025
Net income$32.7M$32.7M2025
Operating income$35.9M$35.9M2025
Total assets$20.2M$20.2M2025
Liabilities$58.7M$58.7M2025
Equity-$38.5M-$38.5M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Atara Biotherapeutics, Inc.’s revenue?
Atara Biotherapeutics, Inc. booked $120.8M in FY2025 revenue, contracting 6.3% year over year — slower than 66% of Healthcare companies we track, at a 27.1% net margin.
Peers · Healthcare
Niagen Bioscience Inc78B+Xencor, Inc.59CMonte Rosa Therapeutics, Inc.54DCareCloud, Inc.73BSmileDirectClub Inc Class A——Outset Medical, Inc.52DNeighbors
San Mateo →Key facts
CEOAnhco Nguyen
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ATRA
Employees13
IPO date2014-10-16
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.